Wize Pharma
Manufacturing · Israel · 51-200 Employees
View Company Info for Free
Overview
Headquarters
5b Hanagar St, Hod HaSharon, Central Dis...Phone Number
+972 722600536Website
www.wizepharma.comRevenue
$24.2 MillionStock Symbol
WIZPIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Wize Pharma
Wize Pharma, Inc. is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including DES. Wize has in-licensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including CCh and Sjögren's syndrome (Sjögren's). LO2A is currently registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES, CCh and Sjögren's and in the Netherlands for the treatment of DES and Sjögren's.Explore more
Wize Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Wize Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Wize Pharma is spiking on competitors!
Product Launch: Get notified when Wize Pharma launches new products
Check if Wize Pharma has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Wize Pharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Wize Pharma
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Wize Pharma has new funding data
Wize Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Wize Pharma had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Wize Pharma
Find more new buyers
Company Profile Activity
Activity Insights
Wize Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Wize Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Wize Pharma.
Wize Pharma financials insights
Gather financial insights about Wize Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$7.5M
Wize Pharma Tech Stack
A closer look at the technologies used by Wize Pharma
Wize Pharma News & Media
Wize Pharma Receives Bonus BioGroup Shares from Escrow and Additional Bonus BioGroup Shares Totaling $1.3 Million
HOD HASHARON, Israel, Jan. 4, 2021 /PRNewswire/ -- Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that, on December 29, 2020, it has completed the transactions contemplated by the previously...Wize Pharma and Cosmos Capital enter into Bid Implementation Agreement
HOD HASHARON, Israel, and SYDNEY, Dec. 30, 2020 /PRNewswire/ -- Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and Cosmos Capital Limited, a leading digital infrastructure provider based in Sydney, Australia,...Wize Pharma Announces Positive Topline Results in Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren's Syndrome
HOD HASHARON, Israel, Nov. 12, 2020 /PRNewswire/ -- Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today reported topline results from its Phase IV clinical trial of its in-license eye drop formula, LO2A, for...Wize Pharma's Strategic Transaction Partner Bonus BioGroup to Present MesenCure Data at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting on May 28-29, 2020
HOD HASHARON, Israel, May 27, 2020 /PRNewswire/ -- Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that Bonus BioGroup (TASE: BONS.TA), a company in which Wize owns an 8.9% equity stake, will...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Wize Pharma
Sign Up For FreeTo access detailed company insights
Wize Pharma, Inc. is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including DES. Wize has in-licensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including CCh and Sjögren's... Read More
